UK markets close in 55 minutes

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
414.13+0.05 (+0.01%)
As of 10:34AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close414.08
Bid413.52 x 800
Ask414.07 x 800
Day's range412.51 - 417.98
52-week range288.01 - 555.77
Avg. volume779,615
Market cap64.811B
Beta (5Y monthly)0.95
PE ratio (TTM)79.30
EPS (TTM)5.22
Earnings date04 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est453.00
  • Zacks

    New Strong Sell Stocks for October 19th

    ACCD, EAT, ILMN, MAXN, and TM have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2021

  • Reuters

    EU antitrust regulators resume Illumina, Grail probe, decision due by Feb. 4

    EU antitrust regulators have resumed their scrutiny of U.S. life sciences company Illumina's bid for Grail Inc after a two-month temporary halt and will decide by Feb. 4 whether to clear the deal, a European Commission filing showed on Tuesday. The EU competition enforcer paused its investigation on Aug. 11 while waiting for Illumina to provide requested data. Last month it sent a statement of objections to Illumina for closing the deal before securing regulatory clearance, warning of interim measures.

  • Motley Fool

    Why Shares of Ilumina Slumped 11.3% in September

    Shares of applied genomics company Ilumina (NASDAQ: ILMN) dropped 11.3% in September, according to data provided by S&P Global Market Intelligence. Ilumina's shares are still up more than 4% this year. The biggest thing hanging over Ilumina is its somewhat controversial purchase of liquid biopsy company Grail, which was once was a division of Ilumina but was spun off in 2016 into a separate company.